Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $21

Benzinga · 1d ago
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target from $17 to $21.